Abstract 85P
Background
Treatment recommendations and benefit of local therapy in oligometastatic disease (OMD) are an era of interest and debate; however, it’s quite difficult to plan RCTs including patients with metastases due to ethical considerations as patients may lose an effective treatment if they are assigned to a control arm, furthermore, most of the clinical literature on OMD is cancer site specific, this study included OMD of different solid tumors.
Methods
In this observational prospective cohort study Patients with stage IV solid tumors who met the criteria of OMD (≤5 metastatic lesions, and or ≤2 organs) with performance status 0-2 were eligible; we studied disease characteristics and outcomes regarding local therapies of OMD.
Results
Two hundred and thirty-four patients with solid tumors met the criteria of OMD, 126 (53.8%) Patients received local therapies; surgery, Radiotherapy (RT), local ablative therapy (group I) and 108 (46.2%) Patients didn’t receive local therapy (group II). Comparing both groups, Group I: patients had significantly younger age, earlier initial TNM stage, higher rates of metachronous onset, symptomatic disease, soft tissue disease, single lesion and or single organ involvement and complete response, but lower rates of managed pulmonary OMD compared to group II. However, no significant association with specific primary cancer site, histological grade, molecular subtype, SUV activity level in PET/CT, type and number of systemic therapy lines, type of OMD (genuine vs. induced and repeated vs. de novo), cut of point of serum tumor markers or any subsequent delay of systemic treatment were noticed with local therapy (p value >0.05) and unexpectedly metastatic size of ≥ 3 cm was more amenable for local therapy (p value ≤0.05). Regarding survival, local therapy of OMD was associated with better PFS and OS: The mean OS in local therapy group was 64 months vs. 38 months in non local therapy patients and the median PFS was not reached in local therapy patients vs. 30 months in no local therapy patients. By multivariate regression analysis; local therapy for OMD is an independent prognostic factor for both PFS and OS.
Conclusions
For selected oligometastatic solid tumor patients, local therapy for OMD could improve PFS and OS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufia University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract